NEW YORK, November 4, 2005—Many of the world’s leading experts on the varicella-zoster virus (VZV)—which causes chickenpox (varicella), shingles (herpes zoster) and postherpetic neuralgia (PHN)—will convene in New York on November 7 to discuss global VZV issues, including: the impact of the vaccine in disease reduction; the FDA’s recent approval of MMRV; the effectiveness of an experimental shingles vaccine in reducing the incidence of shingles; and the poten
New Canaan, CT -- The publication of A Crack in the Shield: Our Unvaccinated Children
WASHINGTON, D.C., Sept. 7, 2005 – The Albert B. Sabin Vaccine Institute (Sabin), a leader in promoting the development and use of safe and effective vaccines to prevent disease, announced receipt of a grant of $150,000 from the Bill & Melinda Gates Foundation for the sponsorship of a vaccine policy colloquium to be held at Cold Spring Harbor, Long Island, New York, October 19-21, 2005.
NEW CANAAN, CT—Thirty-five leading cancer vaccine researchers met to consider medical progress in treating cancer with vaccines during a three-day meeting convened by New Canaan’s Sabin Vaccine Institute (Sabin) held this past June.
NEW CANAAN, CT, JUNE 29, 2005 —The Sabin Vaccine Institute will recognize extraordinary contributors to disease research and healthcare innovations at its black-tie gala beginning at 6:30 p.m. on June 29, 2005 at the University Club in New York City.
WASHINGTON, D.C., June 8, 2005 – The Albert B. Sabin Vaccine Institute, a leader in promoting the development and use of vaccines to prevent disease, today announced that it has received a grant of US$21.8 million from the Bill & Melinda Gates Foundation. The Sabin Vaccine Institute will use this grant—one of the largest awards ever in helminth infection research—to advance its Human Hookworm Vaccine Initiative (HHVI).
NEW CANAAN, CT— Albert Z. Kapikian, MD, physician, medical pioneer and viral diseases researcher, received the prestigious Albert B. Sabin Gold Medal at a ceremony on May 10, 2005. Kapikian is the 13th recipient of this recognition, awarded annually by the Sabin Vaccine Institute to honor achievements by vaccinologists and infectious disease experts.
Recent outbreaks of a deadly diarrheal disease in Central America have galvanized national leaders, doctors, nurses and parents, as they battle against the killer disease known as rotavirus. Though it affects rich and poor children alike, the disease causes most of its devastation in developing countries, where rotavirus strikes mainly infants and young children; each year approximately 500,000 children around the world die from the disease.
WASHINGTON, DC, January 26, 2005—Clinical trials to test the safety of a first-of-its-kind human hookworm vaccine will begin in the Washington, DC area in a couple of months after the U.S. Food and Drug Administration conferred investigational new drug status on the vaccine.